Moderna (MRNA) Gains Ground On Cancer Vaccine Narrative As Valuation Questions Grow

Moderna (MRNA) is back in focus after the firm and Merck said their Phase 3 trial of personalized cancer vaccine intismeran autogene plus Keytruda met its main melanoma goal.

That cancer vaccine update has arrived after a remarkable run for Moderna, with the 90‑day share price return of 195.64% and a very large year to date share price gain. The 1‑year total shareholder return of 712.09% points to powerful momentum that recent trial headlines and new Middle East partnership talks have helped reinforce.

Scan beyond Moderna to see which other mRNA and oncology players are catching similar momentum in our hand picked list of 38 healthcare AI stocks.

Moderna now trades near a four year high while the average analyst target sits far lower, so where does a reasonable view of fair value actually land after this surge?

Most Popular Narrative: 66% Overvalued

Moderna closed at $198.88 while the most followed narrative pegs fair value at $119.56, so the current price bakes in a lot of optimism that needs strong execution to hold.

The dramatic expansion and advancement of Moderna's mRNA pipeline beyond COVID-19, including recent positive late-stage data and upcoming filings for flu, RSV, CMV, oncology, and rare diseases, are likely to diversify the revenue base, capitalize on the rising global burden of infectious and chronic diseases, and materially boost future top-line growth.

See why 214 investors see Moderna as 66% overvalued.

Result: Fair Value of $119.56 (OVERVALUED)

Still, Moderna’s story carries clear pressure points, including reliance on seasonal respiratory vaccines and the risk that cost cuts will eventually weaken the mRNA pipeline.

Find out about the key risks to this Moderna narrative.

Next Steps

Sentiment around Moderna is clearly split. Treat this as your cue to move quickly, review the evidence yourself, and weigh both the upside and the risks highlighted in the 1 key reward and 1 important warning sign.

Looking for more investment ideas beyond Moderna?

If Moderna has your attention, broaden your watchlist now and give yourself more ways to put capital to work intelligently across different themes and risk profiles.

• Target potential mispricing opportunities and look for quality at a discount with the 32 high quality undervalued stocks.
• Build a more resilient core and stress test your downside risk by scanning companies in the 30 resilient stocks with low risk scores.
• Identify possible future leaders early and widen your opportunity set by reviewing the 16 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com